Literature DB >> 2023704

The relationship of the proliferating cell nuclear antigen protein to cis-diamminedichloroplatinum (II) resistance of a murine leukemia cell line P388/CDDP.

H Haneda1, M Katabami, H Miyamoto, H Isobe, T Shimizu, A Ishiguro, T Moriuti, Y Takasaki, Y Kawakami.   

Abstract

We investigated whether the proliferating cell nuclear antigen (PCNA) protein takes part in cis-diamminedichloroplatinum (II) (CDDP) resistance, using a murine leukemia cell line P388 and its CDDP resistant cell line. P388/CDDP was 4 times more resistant to CDDP than P388. The cell lines were maintained in the DBA/2 female mouse peritoneal space. In total cells, the amount of the PCNA protein decreased to 90% in P388 after 1 h CDDP treatment, but that of P388/CDDP increased to 127%. The difference was statistically significant (p = 0.012, n = 5). As for G2/M phase cells, the difference was also significant at 1 h (p = 0.016, n = 5) and at 2 h (p = 0.036, n = 5) after treatment. In P388 the amount of the PCNA protein decreased in accordance with the inhibited cell proliferation, whereas in P388/CDDP, the amount of the PCNA protein increased in spite of the inhibited cell proliferation. This increase of the PCNA protein suggests that the PCNA protein is involved in CDDP resistance of P388/CDDP through enhanced DNA repair synthesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2023704     DOI: 10.1159/000226934

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue.

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  Poor prognostic value of proliferating cell nuclear antigen labelling index in breast carcinoma.

Authors:  M Thomas; M Noguchi; H Kitagawa; K Kinoshita; I Miyazaki
Journal:  J Clin Pathol       Date:  1993-06       Impact factor: 3.411

3.  PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variables.

Authors:  E Leonardi; S Girlando; G Serio; F A Mauri; G Perrone; S Scampini; P Dalla Palma; M Barbareschi
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

4.  Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer.

Authors:  S Aaltomaa; P Lipponen; S Papinaho; K Syrjänen
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Expression of a novel peptide derived from PCNA damages DNA and reverses cisplatin resistance.

Authors:  Robert G Lingeman; Robert J Hickey; Linda H Malkas
Journal:  Cancer Chemother Pharmacol       Date:  2014-09-05       Impact factor: 3.333

6.  Cobalt nanoparticles induce lung injury, DNA damage and mutations in mice.

Authors:  Rong Wan; Yiqun Mo; Zhenyu Zhang; Mizu Jiang; Shichuan Tang; Qunwei Zhang
Journal:  Part Fibre Toxicol       Date:  2017-09-18       Impact factor: 9.400

7.  Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value.

Authors:  P K Lipponen; M J Eskelinen
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

8.  Transient astrocyte-like NG2 glia subpopulation emerges solely following permanent brain ischemia.

Authors:  Denisa Kirdajova; Lukas Valihrach; Martin Valny; Jan Kriska; Daniela Krocianova; Sarka Benesova; Pavel Abaffy; Daniel Zucha; Ruslan Klassen; Denisa Kolenicova; Pavel Honsa; Mikael Kubista; Miroslava Anderova
Journal:  Glia       Date:  2021-07-27       Impact factor: 8.073

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.